RemeGen Co (HKSE:09995) FCF Yield % : -2.28 (As of May. 23, 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, RemeGen Co's Trailing 12-Month Free Cash Flow is HK$-559.9 Mil, and Market Cap is HK$24,057.3 Mil. Therefore, RemeGen Co's FCF Yield % for today is -2.28%.

The historical rank and industry rank for RemeGen Co's FCF Yield % or its related term are showing as below:

HKSE:09995' s FCF Yield % Range Over the Past 10 Years
Min: -25.97 Med: -1.86 Max: -0.35
Current: -2.28

During the past 6 years, the highest FCF Yield % of RemeGen Co was -0.35%. The lowest was -25.97%. And the median was -1.86%.

HKSE:09995's FCF Yield % is ranked better than
78.44% of 1554 companies
in the Biotechnology industry
Industry Median: -14.335 vs HKSE:09995: -2.28

RemeGen Co's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

RemeGen Co FCF Yield % Historical Data

The historical data trend for RemeGen Co's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co FCF Yield % Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-2.91

-1.14

-7.16

-12.64

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial									-	-	-	-	-15.16

Competitive Comparison of RemeGen Co's FCF Yield %

For the Biotechnology subindustry, RemeGen Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's FCF Yield % distribution charts can be found below:

* The bar in red indicates where RemeGen Co's FCF Yield % falls into.

RemeGen Co FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

RemeGen Co's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-2575.377	/	20382.64935
	=	-12.64%

RemeGen Co's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0	*	4	/	20382.64935
	=	0.00%

RemeGen Co FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

RemeGen Co FCF Yield % Related Terms

Thank you for viewing the detailed overview of RemeGen Co's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines